Endoscopic resection of pituitary adenomas has been reported to improve vision function in up to 80%–90% of patients with visual impairment due to these adenomas. It is unclear how these reported rates translate into improvement in visual outcomes and general health as perceived by the patients. The authors evaluated self-assessed health-related quality of life (HR-QOL) and vision-related QOL (VR-QOL) in patients before and after endoscopic resection of pituitary adenomas.
The authors prospectively collected data from 50 patients who underwent endoscopic resection of pituitary adenomas. This cohort included 32 patients (64%) with visual impairment preoperatively. Twenty-seven patients (54%) had pituitary dysfunction, including 17 (34%) with hormone-producing tumors. Patients completed the National Eye Institute Visual Functioning Questionnaire and the 36-Item Short Form Health Survey preoperatively and 6 weeks and 6 months after surgery.
Patients with preoperative visual impairment reported a significant impact of this condition on VR-QOL preoperatively, including general vision, near activities, and peripheral vision; they also noted vision-specific impacts on mental health, role difficulties, dependency, and driving. After endoscopic resection of adenomas, patients reported improvement across all these categories 6 weeks postoperatively, and this improvement was maintained by 6 months postoperatively. Patients with preoperative pituitary dysfunction, including hormone-producing tumors, perceived their general health and physical function as poorer, with some of these patients reporting improvement in perceived general health after the endoscopic surgery. All patients noted that their ability to work or perform activities of daily living was transiently reduced 6 weeks postoperatively, followed by significant improvement by 6 months after the surgery.
Both VR-QOL and patient's perceptions of their ability to do work and perform other daily activities as a result of their physical health significantly improved by 6 months after endoscopic resection of pituitary adenoma. The use of multidimensional QOL questionnaires provides a precise assessment of perceived outcomes after endoscopic surgery.
ABBREVIATIONSHR-QOL = health-related QOL; NEI-VFQ-25 = National Eye Institute Visual Function Questionnaire-25; QOL = quality of life; SF-36 = 36-Item Short Form Health Survey; VR-QOL = vision-related QOL.
Correspondence Neil Duggal, London Health Sciences Centre, University Hospital, 339 Windermere Rd., London, ON N6A 5A5, Canada. email: email@example.com.INCLUDE WHEN CITING Published online October 7, 2016; DOI: 10.3171/2016.7.JNS16200.Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
BiermaszNRvan ThielSWPereiraAMHoftijzerHCvan HemertAMSmitJWA: Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab89:5369–53762004
BiermaszNR, van ThielSW, PereiraAM, HoftijzerHC, van HemertAM, SmitJWA, : Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. 89:5369–5376, 200410.1210/jc.2004-066915531483)| false
DekkersOM, van der KlaauwAA, PereiraAM, BiermaszNR, HonkoopPJ, RoelfsemaF, : Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. 91:3364–3369, 20061678799110.1210/jc.2006-0003)| false
HayashiYKitaDIwatoMFukuiIOishiMTsutsuiT: Significant improvement of intractable headache after transsphenoidal surgery in patients with pituitary adenomas; preoperative neuroradiological evaluation and intraoperative intrasellar pressure measurement. Pituitary19:175–1822016
HazerDBIşıkSBerkerDGülerSGürlekAYücelT: Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg119:1467–14772013
HazerDB, IşıkS, BerkerD, GülerS, GürlekA, YücelT, : Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. 119:1467–1477, 201310.3171/2013.8.JNS1322424074496)| false
MangioneCM, LeePP, GutierrezPR, SpritzerK, BerryS, HaysRD: Development of the 25-Item National Eye Institute Visual Function Questionnaire. 119:1050–1058, 20011144832710.1001/archopht.119.7.1050)| false
McCoulED, BedrosianJC, AkselrodO, AnandVK, SchwartzTH: Preservation of multidimensional quality of life after endoscopic pituitary adenoma resection. 123:813–820, 201510.3171/2014.11.JNS1455926047408)| false
McHorneyCA, WareJEJr, RaczekAE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. 31:247–263, 1993845068110.1097/00005650-199303000-00006)| false
ShinSSGardnerPANgJFarajiAHAgarwalNChivukulaS: Endoscopic endonasal approach for ACTH-secreting pituitary adenomas: outcomes and analysis of remission rates and tumor biochemical activity with respect to tumor invasiveness.. World Neurosurg[epub ahead of print]2015
ShinSS, GardnerPA, NgJ, FarajiAH, AgarwalN, ChivukulaS, : Endoscopic endonasal approach for ACTH-secreting pituitary adenomas: outcomes and analysis of remission rates and tumor biochemical activity with respect to tumor invasiveness.. [epub ahead of print]201526252984)| false
TanemuraE, NagataniT, AimiY, KishidaY, TakeuchiK, WakabayashiT: Quality of life in nonfunctioning pituitary macroadenoma patients before and after surgical treatment. 154:1895–1902, 201210.1007/s00701-012-1473-322922980)| false
WolfA, GoncalvesS, SalehiF, BirdJ, CooperP, Van UumS, : Quantitative evaluation of headache severity before and after endoscopic transsphenoidal surgery for pituitary adenoma. 124:1627–1633, 201610.3171/2015.5.JNS157626495954)| false